Log in

NASDAQ:GNCAGenocea Biosciences Stock Price, Forecast & News

$3.01
0.00 (0.00 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.00
Now: $3.01
$3.13
50-Day Range
$1.81
MA: $2.73
$5.53
52-Week Range
$1.10
Now: $3.01
$5.75
Volume531,715 shs
Average Volume2.57 million shs
Market Capitalization$90.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Read More
Genocea Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.19 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.89 per share

Profitability

Net Income$-38,950,000.00

Miscellaneous

Employees61
Market Cap$90.18 million
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$3.01
0.00 (0.00 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNCA News and Ratings via Email

Sign-up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions

How has Genocea Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Genocea Biosciences' stock was trading at $1.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GNCA stock has increased by 64.5% and is now trading at $3.01.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Genocea Biosciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Genocea Biosciences
.

When is Genocea Biosciences' next earnings date?

Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Genocea Biosciences
.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences Inc (NASDAQ:GNCA) posted its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $0.91 million for the quarter.
View Genocea Biosciences' earnings history
.

What price target have analysts set for GNCA?

3 brokerages have issued 1 year target prices for Genocea Biosciences' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Genocea Biosciences' share price to reach $7.00 in the next year. This suggests a possible upside of 132.6% from the stock's current price.
View analysts' price targets for Genocea Biosciences
.

Has Genocea Biosciences been receiving favorable news coverage?

Press coverage about GNCA stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genocea Biosciences earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Genocea Biosciences
.

Are investors shorting Genocea Biosciences?

Genocea Biosciences saw a increase in short interest in July. As of July 31st, there was short interest totaling 291,300 shares, an increase of 25.8% from the July 15th total of 231,500 shares. Based on an average daily volume of 648,200 shares, the short-interest ratio is presently 0.4 days. Approximately 1.6% of the company's shares are short sold.
View Genocea Biosciences' Short Interest
.

Who are some of Genocea Biosciences' key competitors?

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the following people:
  • Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
  • Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
  • Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
  • Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
  • Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

Who are Genocea Biosciences' major shareholders?

Genocea Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.16%), Virtu Financial LLC (0.12%) and WINTON GROUP Ltd (0.10%). Company insiders that own Genocea Biosciences stock include George Siber, Michael Alfieri, Paul Edward Walker and Peter W Sonsini.
View institutional ownership trends for Genocea Biosciences
.

Which major investors are buying Genocea Biosciences stock?

GNCA stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Virtu Financial LLC, and WINTON GROUP Ltd. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, Paul Edward Walker, and Peter W Sonsini.
View insider buying and selling activity for Genocea Biosciences
.

How do I buy shares of Genocea Biosciences?

Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $3.01.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $90.19 million. The biotechnology company earns $-38,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.

What is Genocea Biosciences' official website?

The official website for Genocea Biosciences is www.genocea.com.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.